Concepedia

Author

Karl‐Georg Simon

Goethe University FrankfurtORCID

Also Known As

C Sick, K G Simon, K SIMON, K Simon, K. G. Simon, K. Simon, K.-G. Simon, K.G. Simon, KIMBERLY SIMON, Karl-Georg Simon

78

Publications

1.2K

Citations

16

H-Index

25

Concepts

All Affiliations

Goethe University FrankfurtCenter for HIV and HepatogastroenterologyMedizinische Hochschule HannoverInstitute for Interdisciplinary MedicineUniversity Medical Center Hamburg-Eppendorf
KS

About

Karl‐Georg Simon is an author at Goethe University Frankfurt specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

675

2

Hepatology

4

4

183

3

Immunology

2

2

107

4

Pharmacology

2

2

322

5

Pathology

1

1

18

Karl‐Georg Simon

×

18

Publications

987

Citations

14

H-Index

YearCitations

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Thomas Berg, Karl‐Georg Simon, Stefan Mauss,

Journal of Hepatology

2017

309

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Julia Dietz, S. Süsser, Johannes Vermehren,

Gastroenterology

2017

147

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

Florian van Bömmel, Kerstin Stein, R Heyne,

Journal of Hepatology

2023

84

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)

Patrick Ingiliz, Stefan Christensen, Torben Kimhofer,

Clinical Infectious Diseases

2016

72

Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era

Patrick Ingiliz, Malte H. Wehmeyer, Christoph Boesecke,

Clinical Infectious Diseases

2019

69

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Peter Buggisch, Johannes Vermehren, Stefan Mauss,

Journal of Hepatology

2017

61

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection

Johann von Felden, Johannes Vermehren, Patrick Ingiliz,

Alimentary Pharmacology & Therapeutics

2018

53

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

T. Witthoeft, D. Hueppe, C John,

Journal of Viral Hepatitis

2010

31

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

Julia Dietz, Beat Müllhaupt, Peter Buggisch,

Journal of Hepatology

2022

23

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen

Adolfo de Salazar, Julia Dietz, Velia Chiara Di Maio,

Journal of Antimicrobial Chemotherapy

2020

21

Page 1